From: Clinical and serological evaluation of a novel CENP-A peptide based ELISA
Berlin | Leuven | Calgary | Neuss | All | |
---|---|---|---|---|---|
SSc | 45/126 (35.7%) | 30/84 (35.7%) | 29/113 (25.7%) | 8/11 (72.2%) | 112/334 (33.5%) |
lSSc | 26/52 (50.0%) | 26/29 (89.7%) | n.d. | n.d. | 52/81 (64.2%) |
dSSc | 3/26 (11.5%) | 3/29 (10.3%) | n.d. | n.d. | 6/55 (10.9%) |
Controls all | 4/120 (3.3%) | 9/226 (4.0%) | 7/127 (5.5%) | 5/321 (1.6%) | 25/794 (3.1%) |
SLE | 4/109 (3.7%) | 4/69 (5.8%) | n.d. | 1/36 (2.8%) | 9/214 (4.2%) |
RA | n.d. | 0/25 (0.0%) | n.d. | 0/15 (0.0%) | 0/40 (0.0%) |
SjS | 0/2 (0.0%) | 2/35 (5.7%) | n.d. | 0/7 (0.0%) | 2/44 (4.6%) |
MCTD | 0/3 (0.0%) | 0/12 (0.0%) | n.d. | 0/3 (0.0%) | 0/18 (0.0%) |
Overlaps | 0/4 (0.0%) | 0/3 (0.0%) | n.d. | 0/9 (0.0%) | 0/16 (0%) |
PM | n.d. | 1/14 (7.1%) | 4/28 (8.3%) | 0/1 (0.0%) | 5/43 (11.6%) |
DM | n.d. | 1/23 (4.4%) | n.d. | n.d. | 1/23 (4.4%) |
PBC | n.d. | n.d. | 3/51 (5.9%) | 0/3 (0.0%) | 3/54 (5.6%) |
WG | n.d. | n.d. | n.d. | 0/3 (0.0%) | 0/3 (0.0%) |
Others | 0/2 (0.0%) | n.d. | n.d. | 3/78 (3.9%) | 3/80 (4.6%) |
CFS | n.d. | 0/36 (0.0 %) | n.d. | n.d. | 0/36 (0.0%) |
CD | n.d. | n.d. | 0/48 (0.0%) | n.d. | 0/48 (0.0%) |
HD | n.d. | 1/9 (11.1%) | n.d. | 0/166 (0.0%) | 1/175 (0.6%) |
Sensitivity | 35.7% | 35.7% | 25.7% | n.d. | 33.5% |
Specificity | 96.7% | 96.0% | 94.5% | 98.1 | 96.9%. |
AUC | 0.80 | 0.68 | 0.42 | n.d. | 0.67 |